The purpose of the Agilent Early Career Professor Award is to:

Promote and encourage excellent research enabling measurements of importance to Agilent Technologies and the world
Establish strong collaborative relationships between Agilent researchers and leading professors early in their career
Build the prominence of Agilent as a sponsor of university research

Focus Topic: Contributions to environmental sustainability through development of green analytical technologies, methods, or laboratory working environments.

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
This Funding Opportunity Announcement does not accept applications proposing clinical trials.

The PhRMA Foundation Faculty Starter Grant in Drug Discovery Targets and Pathways offers financial support to individuals beginning independent careers in drug discovery research at the faculty level at an accredited U.S. university.

Successful drug discovery involves the innovative application and integration of multiple scientific disciplines to create efficacious, safe, and differentiated treatment options for patients. The PhRMA Foundation seeks to fund novel early-stage, exploratory drug discovery research with the potential for translation to humans, including biological validation of potential drug targets, signaling pathways, or mechanisms of disease. 

Research topics could include, but are not limited to:  
Genomics and Proteomics 
Cellular and Molecular Biology 
Design and Generation of Pharmacological Tools  
In Vitro and/or In Vivo Pharmacology 
Protein Biochemistry 
Molecular Modelling 
Structural Biology 
Cell Imaging 
Single Cell Analysis 
Artificial Intelligence and Computational Approaches 
Projects that focus exclusively on single aspects such as identification of and development of assays for single targets, chemical probes, biomarkers, chemical library screening, or diagnostics will not be considered for review. Project aims should have a high likelihood of completion in the award timeframe.

Translational medicine is a scientific discipline focused on turning observations in the laboratory, clinic, and community into medicines, diagnostics, or other interventions that improve human health.

Translational medicine fosters a patient-focused research cycle that stretches from the lab bench to the patient bedside and back to the lab again. This includes adapting basic research discoveries in cells, tissues, and animals for application in humans and then taking the knowledge of what did and didn’t work in the clinic back to the bench.

Given the breadth of the discipline, the PhRMA Foundation’s Translational Medicine Program focuses specifically on novel research that uses the “bedside to bench” approach to address unmet needs in the diagnosis, treatment, and prevention of disease. The Foundation seeks research proposals that focus on identifying unmet clinical needs and developing new diagnostic, experimental, and computational approaches and technologies to improve patient care and management.

Applicants should work with clinical collaborators to identify unmet clinical needs. Proposals should integrate innovative technologies, with advanced biological, chemical, diagnostic, and pharmacological sciences and engineering methodologies in areas that include but not are limited to:
Genetics (Molecular, Pharmaco-, Population, Medical)
Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative)
Systems (Biology and Pharmacology)
Pathways and Networks
Integrative Biology
Modeling and Simulation
Target Identification and Validation
Biomarker Identification and Validation
Molecular Epidemiology
Imaging
Disease Modeling

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical, clinical, behavioral and social sciences research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or the National Human Genome Research Institute (NHGRI). New investigators at the time of award under this FOA will have had less than $125,000 direct costs of combined research funding (excluding NIH training and NIH career awards). This R21 will support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate transition to research independence. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Components of Participating Organizations:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Human Genome Research Institute (NHGRI)

The New Investigator Grant advances the scientific training of the next generation of orthopaedic physician-scientists by providing seed and start-up funding for promising research projects.Residents, fellows, and orthopaedic surgeons having completed formal training within the last four years may apply. View the RFA on proposalCentral for complete eligibility requirements.